IgA Nephropathy Market Projected to Reach $11.6 Billion by 2036

The market for IgA Nephropathy (IgAN) is projected to experience substantial growth over the next decade, expanding from an estimated $1.5 billion in 2025 to $11.6 billion by 2036. This represents a compound annual growth rate of 18.6% during the forecast period of 2026–2036, according to analysis by DelveInsight.

Several factors are expected to fuel this market expansion. These include improvements in diagnostic practices, increased disease awareness, and a wider adoption of kidney biopsies for diagnosis. IgAN is an autoimmune condition that damages the glomeruli in the kidneys. Current treatments aim to reduce proteinuria, manage blood pressure, and slow disease progression, as no cure currently exists.

The IgAN treatment landscape is evolving with the introduction and development of novel therapies targeting underlying disease mechanisms. Approved drugs include iptacopan, atrasentan, and budesonide. The recent US FDA approval of sibeprenlimab offers a new, first-in-class therapy that modifies the disease course. Multiple other pipeline therapies are in late-stage development.

DelveInsight's analysis indicates approximately 415,000 diagnosed prevalent cases of IgAN across the major markets in 2025. The disease shows a higher prevalence in males and commonly affects individuals aged 18–45, although it impacts all age groups. Germany accounts for the highest disease burden within the EU4 and UK region. The increasing diagnosed patient population and the anticipated launch of new, mechanism-based therapies are key drivers for the market's future trajectory.